{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:44:28Z","timestamp":1794037468682,"version":"4.8.0"},"reference-count":101,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"unspecified","delay-in-days":421,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Not applicable","award":["No grant"],"award-info":[{"award-number":["No grant"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2019,9,2]]},"DOI":"10.1080\/1744666x.2019.1648209","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T08:31:21Z","timestamp":1567672281000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":197,"title":["An update on generalized pustular psoriasis"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[{"name":"Queen\u2019s University","place":["Peterborough, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby S.","family":"Van Voorhees","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School","place":["Norfolk, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1968.tb11947.x"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14386"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680080075005"},{"key":"e_1_3_6_6_1","unstructured":"Morrison AO. Pustular psoriasis. 2017 [cited 2018 Aug 08 ]. Medscape. Available from: https:\/\/emedicine.medscape.com\/article\/1108220-overview"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555766871"},{"issue":"6","key":"e_1_3_6_8_1","first-page":"669","article-title":"Generalized pustular psoriasis (Zumbusch): a\n\t\t\t\t\t\tFrench epidemiological survey","volume":"16","author":"Augey F","year":"2006","unstructured":"Augey F , Renaudier P , Nicolas JF . Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006 Nov-Dec;16(6):669\u2013673.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14523"},{"key":"e_1_3_6_10_1","unstructured":"MorphoSys . MorphoSys announces approval of Tremfya\u00ae (guselkumab) for the treatment of moderate to severe forms of psoriasis and psoriatic arthritis in Japan. 2018 Apr 6 [cited 2018 Nov 12]. Available from: https:\/\/www.morphosys.com\/media-investors\/media-center\/morphosys-announces-approval-of-tremfyar-guselkumab-for-the-treatment"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20305"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12070"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12863"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S125784"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S98954"},{"key":"e_1_3_6_17_1","unstructured":"Kandolf Sekulovic L . Overview of subcornal pustular dermatosis. Medscape. 2016 [cited 2018 Aug 08 ]. Available from: https:\/\/emedicine.medscape.com\/article\/1124252-overview#a1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17081214"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-002-0371-6"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013068"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.288"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.04.005"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2018.01.012"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2018.05.004"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.04.003"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08156.x"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586900-000000000-00000"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.361"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.02.006"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.056"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13699"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2808"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14139"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2011.07.022"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.230"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.09.043"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.214"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.038"},{"key":"e_1_3_6_40_1","unstructured":"National Institutes of Health . IL36RN gene interleukin 36 receptor antagonist U.S. National Library of Medicine; [cited 2018 Aug 18 ]. Available from: https:\/\/ghr.nlm.nih.gov\/gene\/IL36RN"},{"key":"e_1_3_6_41_1","unstructured":"National Institutes of Health . CARD14 gene caspase recruitment domain family member 14: U.S. National Library of Medicine; [cited 2018 Aug 18 ]. Available from: https:\/\/ghr.nlm.nih.gov\/gene\/CARD14"},{"key":"e_1_3_6_42_1","unstructured":"National Institutes of Health . AP1S3 gene adaptor related protein complex 1 subunit sigma 3: U.S. National Library of Medicine; [cited 2018 Aug 18]. Available from: https:\/\/ghr.nlm.nih.gov\/gene\/AP1S3"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.490"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.03.012"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.05.010"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02239"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.618"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.10.021"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500"},{"issue":"5","key":"e_1_3_6_50_1","first-page":"1092","article-title":"Th17 cytokines\n\t\t\t\t\t\tinterleukin (IL)-17 and IL-22 modulate distinct inflammatory and\n\t\t\t\t\t\tkeratinocyte-response pathways","volume":"159","author":"Nograles KE","year":"2008","unstructured":"Nograles KE , Zaba LC , Guttman-Yassky E , et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008 Nov;159(5):1092\u20131102.","journal-title":"Br J Dermatol"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12272"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155215"},{"key":"e_1_3_6_53_1","first-page":"120347541877335","article-title":"Systemic monotherapy\n\t\t\t\t\t\ttreatments for generalized pustular psoriasis: a systematic\n\t\t\t\t\t\treview","volume":"1","author":"Zhou LL","year":"2018","unstructured":"Zhou LL , Georgakopoulos JR , Ighani A , et al. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;1:1203475418773358.","journal-title":"J Cutan Med Surg"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294"},{"key":"e_1_3_6_55_1","unstructured":"Janssen Biotech I . Prescribing information: TREMFYA (guselkumab). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761061s000lbl.pdf"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431171"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0117-6"},{"key":"e_1_3_6_58_1","unstructured":"Janssen Biotech I . Prescribing information: REMICADE (infliximab). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103772s5385lbl.pdf"},{"key":"e_1_3_6_59_1","unstructured":"Amgen Inc . Prescribing information: ENBREL\u00ae (etanercept). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103795s5563s5564lbl.pdf"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2016.12.003"},{"key":"e_1_3_6_61_1","unstructured":"AbbVie Inc . Prescribing information: HUMIRA (adalimumab). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s406lbl.pdf"},{"key":"e_1_3_6_62_1","unstructured":"Swedish Orphan Biovitrum AB (publ) . Prescribing information: KINERET\u00ae (anakinra). [cited 20 Aug 2018]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103950s5182lbl.pdf"},{"key":"e_1_3_6_63_1","unstructured":"Novartis Pharmaceuticals Corporation . Prescribing information: ILARIS\u00ae (canakinumab). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125319s088lbl.pdf"},{"key":"e_1_3_6_64_1","unstructured":"Novartis Pharmaceuticals Corporation . Prescribing information: COSENTYX\u00ae (secukinumab). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125504s013lbl.pdf"},{"key":"e_1_3_6_65_1","unstructured":"Valeant Pharmaceuticals North America LLC . Prescribing information: SILIQ\u2122 (brodalumab). [cited 2018 Aug 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf"},{"key":"e_1_3_6_66_1","unstructured":"Eli Lilly and Company . Prescribing information: TALTZ (ixekizumab). [cited 2018 Aug 20 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125521s009lbl.pdf"},{"key":"e_1_3_6_67_1","unstructured":"Janssen Biotech I . Prescribing information: STELARA\u00ae (ustekinumab). [cited 2018 Aug 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90285-6"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1409-7"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/561018"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2012.11124"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.032"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1997.tb01697.x"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06181.x"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1977.tb15055.x"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1309349"},{"key":"e_1_3_6_79_1","unstructured":"American Academy of Dermatology . Psoriasis: recommendations for cyclosporine. [cited 2019 Jan 22 ]. Available from: https:\/\/www.aad.org\/practicecenter\/quality\/clinical-guidelines\/psoriasis\/systemic-agents\/recommendations-for-cyclosporine"},{"key":"e_1_3_6_80_1","unstructured":"Medscape . Dapsone (Rx). [cited 2018 Nov 15 ]. Available from: https:\/\/reference.medscape.com\/drug\/aczone-dapsone-342559#10"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2017.04.013"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418758986"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.07.007"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.037"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12342"},{"issue":"6","key":"e_1_3_6_87_1","first-page":"e652","article-title":"Biologics and pediatric generalized pustular\n\t\t\t\t\t\tpsoriasis: an emerging therapeutic trend","volume":"8","author":"Saikaly SK","year":"2016","unstructured":"Saikaly SK , Mattes M . Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend. Cureus. 2016 Jun 22;8(6):e652.","journal-title":"Cureus"},{"key":"e_1_3_6_88_1","unstructured":"US Food and Drug Administration . Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling (Federal Register\/Vol. 73 No. 104\/Thursday May 29 2008). [cited 2019 Jan 23 ]. Available from: https:\/\/www.govinfo.gov\/content\/pkg\/FR-2008-05-29\/pdf\/E8-11806.pdf"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-1-201007060-00030"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12548"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14685"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13614"},{"key":"e_1_3_6_93_1","volume-title":"Poster presented at the 2018 European\n\t\t\t\t\t\tAcademy of Allergy and Clinical Immunology (EAACI) Congress","author":"Khanskaya I","unstructured":"Khanskaya I , Pinkstaff J , Marino MH , et al. A phase 1 study of ANB019, an anti-IL-36 receptor monoclonal antibody, in healthy volunteers. Poster presented at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress; 2018 May 26\u201330; Munich, Germany. [cited 2018 Aug 14 ]. Available from: https:\/\/www2.anaptysbio.com\/wp-content\/uploads\/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1811317"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0751"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12868"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12773"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14636"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2019.1648209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T08:12:59Z","timestamp":1754899979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2019.1648209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,2]]}},"alternative-id":["10.1080\/1744666X.2019.1648209"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2019.1648209","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}